Provided by Tiger Trade Technology Pte. Ltd.

Assertio Holdings, Inc.

12.74
+1.129.64%
Post-market: 12.15-0.5900-4.63%19:28 EST
Volume:60.91K
Turnover:761.10K
Market Cap:81.75M
PE:-2.81
High:12.95
Open:11.69
Low:11.61
Close:11.62
52wk High:15.15
52wk Low:7.71
Shares:6.42M
Float Shares:5.68M
Volume Ratio:1.25
T/O Rate:1.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.5263
EPS(LYR):-3.4500
ROE:-24.48%
ROA:-4.17%
PB:0.77
PE(LYR):-3.69

Loading ...

Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Agenus (AGEN) and Assertio Therapeutics (ASRT)

TIPRANKS
·
Jan 21

Assertio Holdings, Inc. Regains Compliance With Nasdaq Listing Requirements

THOMSON REUTERS
·
Jan 13

Assertio Publishes Study Showing Rolvedon Safe and Effective for Same-Day Dosing with TC Chemotherapy

Reuters
·
Jan 10

Assertio Announces Publication of Rolvedon® Same-Day Dosing Clinical Trial

THOMSON REUTERS
·
Jan 10

Assertio Holdings Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 05

Assertio Holdings Inc : H.c. Wainwright Adjusts Target Price to $35 From $3 to Reflect 1-for-15 Reverse Stock Split

THOMSON REUTERS
·
Jan 05

Assertio Therapeutics trading halted, news pending

TIPRANKS
·
Dec 25, 2025

Assertio Holdings, Inc.'s (NASDAQ:ASRT) Shares Lagging The Industry But So Is The Business

Simply Wall St.
·
Dec 24, 2025

Assertio to Effect 1-for-15 Reverse Stock Split

MT Newswires Live
·
Dec 23, 2025

Assertio Holdings Announces 1-for-15 Reverse Stock Split

Reuters
·
Dec 23, 2025

Assertio Therapeutics Announces Leadership Change with CEO Resignation

TIPRANKS
·
Nov 22, 2025

Assertio Holdings CEO Brendan O'Grady Resigns

Reuters
·
Nov 22, 2025

Assertio Holdings, Inc. Q3 Adjusted EPS USD 0.18 Vs. IBES Estimate USD -0.07

Reuters
·
Nov 20, 2025

Director David Matthew Stark Reports Disposal of Assertio Holdings Inc. Common Shares

Reuters
·
Nov 13, 2025

Immix Biopharma Appoints Michael Grabow as Chief Commercial Officer

Reuters
·
Nov 12, 2025

Assertio Therapeutics (ASRT) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Nov 11, 2025

Assertio Therapeutics Promotes Paul Schwichtenberg to President

TIPRANKS
·
Nov 11, 2025

Pharma firm Assertio Q3 adjusted EPS beats estimates on strong Rolvedon sales

Reuters
·
Nov 11, 2025

Assertio Holdings Q3 Adj. EPS $0.18 Beats $(0.09) Estimate, Sales $49.459M Beat $27.020M Estimate

Benzinga
·
Nov 11, 2025

BRIEF-Assertio Holdings, Inc. Q3 Adjusted EPS USD 0.18 Vs. IBES Estimate USD -0.07

Reuters
·
Nov 11, 2025